MedTrace Logo

A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record

NCT06642272 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 17200

Last updated 2024-11-05

No results posted yet for this study

Summary

The aim of this clinical trial is investigate the comparative effectiveness of empagliflozin and dapagliflozin for the treatment of diabetes, chronic kidney disease, and heart failure.

Patients who are prescribed either empagliflozin or dapagliflozin, as part of daily clinical practice at the participating sites, will be included in the study. Treatment will be randomized automatically through the electronic health record software in clusters defined by time of day.

https://www.appletreestudy.com

Conditions

  • Diabetes Mellitus, Type 2
  • Heart Failure
  • Chronic Kidney Diseases

Interventions

DRUG

Empagliflozin 10 MG

Once daily

DRUG

Dapagliflozin 10 MG

Once daily

Sponsors & Collaborators

  • Herlev and Gentofte Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-10
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06642272 on ClinicalTrials.gov